Symmetry Peak Management’s Ginkgo Bioworks DNA Stock Holding History

Symmetry Peak Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-773	Closed	-$125K	–	38
2022 Q1	$125K	Buy	+773	New	+$150K	0.2%	36
2021 Q4	–	Sell	-2,143	Closed	-$993K	–	17
2021 Q3	$993K	Buy	+2,143	New	+$1.04M	1.05%	12

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Symmetry Peak Management's DNA Position: Q2 2023 in Review

Symmetry Peak Management sold out of Ginkgo Bioworks (DNA) in Q2 2023, closing a stake of 2,125 shares — an estimated $113K sold.

Symmetry Peak Management first reported a position in DNA in Q1 2023 and held it in 1 quarter. The position peaked at $113K in Q1 2023. 315 funds tracked by Wall St. Rank hold DNA as of Q2 2023.

Symmetry Peak Management reported no remaining Ginkgo Bioworks position as of Q2 2023 after selling out during the quarter.
Symmetry Peak Management sold 2,125 Ginkgo Bioworks shares in Q2 2023, an estimated $113K.
Symmetry Peak Management first reported a position in Ginkgo Bioworks in Q1 2023 and held it in 1 quarter.
Symmetry Peak Management's Ginkgo Bioworks position peaked at $113K in Q1 2023.
315 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2023.

Based on Symmetry Peak Management's 13F filing for Q2 2023, filed 14 Aug 2023.